Detection of autism spectrum disorder-related pathogenic trio variants by a novel structure-based approach.
Sadhna Rao, Anastasiia Sadybekov, David C DeWitt and 3 others
PMID 38566250WHAT IT FOUND
Structure-based modeling correctly predicted 75% of deleterious TRIO mutations in rat brain slices.
This method identifies genetic variants disrupting synapse function, aiding diagnosis of autism spectrum disorder and intellectual disability. It does not test clinical interventions or patient outcomes.
Key findings
01Experimental validation of eight mutations predicted as disruptive showed a 75% prediction success rate.
02Control mutations predicted to be benign were found to have no impact on TRIO function, placing overall accuracy for all mutations at 80%.
03TRIO-9 E1299W expression in neurons resulted in a marked decrease in AMPAR-eEPSC amplitude, indicative of a dominant negative effect.
STILL TO COME
How it was doneWhat they found
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The study was conducted in rat brain tissue and cell lines, not in human patients. It did not assess clinical outcomes, behavior, or communication skills in people. The method cannot predict whether a person with a detected mutation will actually develop symptoms. Orthogonal validation in cell lines did not always match results from the more complex brain slice model.
Declared interests
Funded by the National Institute of Mental Health and the National Institute of Neurological Disorders and Stroke.
The easy way to misread this
Do not interpret this as evidence that genetic testing changes clinical therapy or patient outcomes. The study validates a computational method for predicting protein dysfunction in animal tissue, not a clinical tool for guiding treatment decisions.